Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
Respira Therapeutics Enters into Agreement with Gossamer Bio Granting Gossamer Option to Acquire Respira from Samsara BioCapital
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On?Demand Vardenafil for Pulmonary Hypertension
Red Metals Corp Invites Shareholders and Investment Community to Visit Them at Booth 2538 at PDAC 2026 in Toronto, March 1-4
Silver Hammer Closes CDN$3,913,617 Non-Brokered Private Placement Pursuant to Listed Issuer Exemption
